News / Taiwan / cnyes
Health Supplement Firm Tengshi Cleared for OTC Listing
Consumer Non-Durables · Household/Personal Care · cnyes · 2026-09-09
7889
Tengshi, a developer of human and pet health supplements, has received approval for its OTC listing, reporting strong earnings and a dual-growth strategy.
What Happened
OTC Listing Approval: Tengshi (7889), a developer specializing in human and pet health supplements, has officially received approval from the Taipei Exchange (TPEx) for its upcoming OTC listing. The company, led by Chairman Zhang Zhixiang, is supported by underwriters including KGI Securities, Taishin Securities, and Fubon Securities.
Financial Performance: The company reported a net profit of NT$45.87 million for the first half of 2026, translating to an earnings per share (EPS) of NT$2.24. Currently, Tengshi is trading on the Emerging Stock Board at approximately NT$75 per share, reflecting investor confidence in its growth trajectory.
Core Business Strategy: Tengshi focuses on the development, marketing, and brand management of health supplements for both humans and pets. The company has successfully implemented a dual-engine business model that leverages growth in both the human wellness and pet health sectors.
Future Outlook: With the OTC listing process moving forward, Tengshi aims to further solidify its brand presence and market share. The company plans to continue executing its dual-engine strategy to maintain stable growth momentum in the competitive health supplement industry.